| __timestamp | Amgen Inc. | Dyne Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4422000000 | 1145000000 |
| Thursday, January 1, 2015 | 4227000000 | 2028000000 |
| Friday, January 1, 2016 | 4162000000 | 2281000000 |
| Sunday, January 1, 2017 | 4069000000 | 2932000000 |
| Monday, January 1, 2018 | 4101000000 | 24000 |
| Tuesday, January 1, 2019 | 4356000000 | 271000 |
| Wednesday, January 1, 2020 | 6159000000 | 700000 |
| Friday, January 1, 2021 | 6454000000 | 1088000 |
| Saturday, January 1, 2022 | 6406000000 | 3345000 |
| Sunday, January 1, 2023 | 8415000000 | 2461000 |
| Monday, January 1, 2024 | 12858000000 |
Cracking the code
In the ever-evolving landscape of biotechnology, understanding the cost of revenue is crucial for assessing a company's financial health. Amgen Inc., a stalwart in the industry, has seen its cost of revenue grow by approximately 90% from 2014 to 2023, reflecting its expanding operations and market reach. In contrast, Dyne Therapeutics, Inc., a newer player, experienced a dramatic fluctuation, with costs peaking in 2017 and then stabilizing at lower levels. This volatility highlights the challenges faced by emerging biotech firms in managing production costs while scaling operations. Notably, Amgen's cost of revenue in 2023 was nearly 3,400% higher than Dyne's, underscoring the disparity in scale and market presence. As the biotech sector continues to innovate, these insights into cost management will be pivotal for investors and stakeholders alike.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Amgen Inc.
Cost of Revenue Comparison: Pfizer Inc. vs Dyne Therapeutics, Inc.
Amgen Inc. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Amgen Inc. vs Walgreens Boots Alliance, Inc.
Cost of Revenue Trends: Amgen Inc. vs HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down BeiGene, Ltd. and Dyne Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Wave Life Sciences Ltd. vs Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs Dyne Therapeutics, Inc.